Toggle Nav
Close
  • Menu
  • Setting

Concanamycin A

Catalog No.
A8633
V-type (vacuolar) H+-ATPase inhibitor
Grouped product items
SizePriceStock Qty
100ug
$165.00
In stock
1mg
$410.00
In stock
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Concanamycin A (CAS 80890-47-7) is a selective inhibitor of vacuolar-type ATPase (V-ATPase), displaying an IC50 of approximately 10 nM. Its mechanism involves direct binding to the V(o) subunit c of V-ATPase, thereby inhibiting proton transport across cell membranes. Through blockade of V-ATPase activity, concanamycin A inhibits endosomal acidification, disrupts intracellular trafficking processes, and interferes with extracellular matrix pH maintenance, resulting in apoptosis induction in tumor cells, including oral squamous cell carcinoma and prostate cancer lines, and reduced tumor cell invasiveness. It is employed extensively in cancer biology research to investigate V-ATPase-mediated pathways and explore therapeutic resistance mechanisms.

Product Citation

Chemical Properties

Physical AppearanceA solution in acetonitrile. To change the solvent, simply evaporate the acetonitrile under a gentle stream of nitrogen and immediately add the solvent of choice.
StorageStore at -20°C
M.Wt866.09
Cas No.80890-47-7
FormulaC46H75NO14
SolubilityLimited solubility, soluble in DMSO
SDFDownload SDF
Canonical SMILESCCC1C(C(CC(=CC=CC(C(OC(=O)C(=CC(=CC(C1O)C)C)OC)C(C)C(C(C)C2(CC(C(C(O2)C=CC)C)OC3CC(C(C(O3)C)OC(=O)N)O)O)O)OC)C)C)O
Shipping ConditionSmall Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips We do not recommend long-term storage for the solution, please use it up soon.

Protocol

Cell experiment [1,2]:

Cell lines

HCT-116, DLD-1, Colo206F, HeLa cells, Androgen-dependent (LNCaP) and androgen-independent (C4-2B) cells.

Preparation method

This compound is limited soluble in DMSO. General tips for obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Reacting condition

20 nM, 60 min

Applications

CCA effectively attenuated the TRAIL-induced activation of caspases in TRAIL-sensitive colorectal cancer cell lines. In CCA-treated Colo206F cells, the number of M30-positive apoptotic cells gradually increased and almost reached the proportion seen in untreated cells within 3–4h after the addition of TRAIL. Treatment with CCA resulted in a lack of apoptosis-related chromatin condensation in DLD-1 cells incubated with TRAIL for 90 min. Treatment with nanomolar concentrations of concanamycin A reduced the in vitro invasion in LNCaP and C4-2B cell types by 80%.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Horova V, et al., Inhibition of vacuolar ATPase attenuates the TRAIL-induced activation of caspase-8 and modulates the trafficking of TRAIL receptosomes. FEBS J, 2013. 280(14).

[2]. Michel V, et al., Inhibitors of vacuolar ATPase proton pumps inhibit human prostate cancer cell invasion and prostate-specific antigen expression and secretion. Int J Cancer. 2013.132(2).

Quality Control

Quality Control & MSDS

View current batch:

Chemical structure

Concanamycin A

Related Biological Data

Concanamycin A